EP
INDV icon

Essential Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Essential Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Hold
17
– – ﹤0.01% 2392
2026
Q1 		$518 Sell
17
-61
-78% -$2.02K ﹤0.01% 2427
2025
Q4 		$2.8K Buy
78
+74
+1,850% +$2.26K ﹤0.01% 1681
2025
Q3 		$96 Buy
+4
New +$84 ﹤0.01% 2498

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's INDV Position: Q2 2026 in Review

Essential Partners held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 17 shares worth $698. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Essential Partners first reported a position in INDV in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.8K in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Essential Partners held 17 shares of Indivior Pharmaceuticals worth $698 as of Q2 2026.
  • Essential Partners left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2392 holding.
  • Essential Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Indivior Pharmaceuticals position peaked at $2.8K in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.